Natalie S. Callander, MD, on Newly Diagnosed Multiple Myeloma: What Early-Phase Trials Suggest

Posted: Wednesday, September 27, 2017

Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses three early-phase studies on various agents, including daratumumab, carfilzomib, lenalidomide, and others, and how these findings may influence the options available to newly diagnosed patients.